Search

Nearly 100% of UT Southwestern Medical School students matched to residency programs – well above the national average of 94%.

Myron Frederick Weiner, M.D., Professor Emeritus of Psychiatry at UT Southwestern Medical Center and a noted clinical researcher in geriatric psychiatry and Alzheimer’s disease, died July 17 in Dallas. He was 89.

A new type of developmental disability caused by mutations in a gene known as CBX1 has been discovered by a UT Southwestern Medical Center researcher and his colleagues. The findings, reported in Genetics in Medicine, offer insight into the role this gene plays in development and could eventually

Catherine Spong, M.D., Chair and Professor of Obstetrics and Gynecology at UT Southwestern Medical Center, has been elected to the National Academy of Medicine (NAM) in recognition of her significant impact on the field of maternal-fetal medicine, her leadership in women’s health research, and her

Children who undergo expansive genetic sequencing may not be getting the thorough DNA analysis their parents were expecting, say experts at UT Southwestern Medical Center.

Using machine learning tools to analyze hundreds of proteins, UT Southwestern researchers have identified a group of biomarkers in blood that could lead to an earlier diagnosis of children with autism spectrum disorder (ASD) and, in turn, more effective therapies sooner.

Blocking a molecule that draws sensory nerves into musculoskeletal injuries prevents heterotopic ossification (HO), a process in which bone abnormally grows in soft tissue during healing

Reuben Arasaratnam, M.D., M.P.H., Assistant Professor of Internal Medicine at UT Southwestern, has been named one of 11 2022 Scholars in Diagnostic Excellence by the National Academy of Medicine (NAM).

Interstitial pneumonia with autoimmune features (IPAF) is a disease with many possible causes and no standard of care, making it particularly difficult to treat. While immunosuppressant drugs are primarily prescribed, they don’t work for all patients.

– In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells, ARO-HIF2, effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC).